Analysis of biomarkers in melanoma patients receiving ICI treatments: pre-vs post in responders and progressors
Background:
Study of biomarkers of immune-related adverse events and responses in patients treated with immune checkpoint inhibitors may shed light into mechanisms of resistance, T cell exhaustion and other combinatorial therapies. The elevated levels of such biomarkers have potential to predict whether a treatment of PD-1 or PD-1/CTLA-4 antagonist combination will be effective in a certain melanoma patient. Therefore, it may potentially guide healthcare providers to change treatment plans.
